Press Releases
  Date Title View
ROCKVILLE, Md., July 20, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the second quarter of 2016 after 5:...
Posted: Jul 20, 2016
ROCKVILLE, Md., June 22, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced  the issuance on June 21, 2016 of a seventh patent (number 9,370,525) by the United States Paten...
Posted: Jun 22, 2016
ROCKVILLE, Md., June 16, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it remains in discussions with the FDA regarding its Supplemental New Drug Application, or ...
Posted: Jun 16, 2016
ROCKVILLE, Md., June 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on May 31, 2016 of a sixth patent (number 9,351,975) by the United States Patent an...
Posted: Jun 2, 2016
ROCKVILLE, Md., May 24, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investo...
Posted: May 24, 2016
ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infrin...
Posted: May 10, 2016
First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter of 2015.Operating income for first quarter 2016 was $5.3 million, a 55.0% increase over the first quarter of 2015.   Diluted earni...
Posted: May 3, 2016
ROCKVILLE, Md., April 19, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2016 af...
Posted: Apr 19, 2016
Net product sales for fourth quarter 2015 were $42.6 million, a 39.6% increase over the same quarter of 2014 and a 10.5% increase over third quarter 2015.  Net product sales for full year 2015 were $143.5 million, a 60.2% increase over full year 2014. Operating income for fourth quarter 2015 was $6.8 million, a 44.8% increase over operating income ...
Posted: Mar 2, 2016
ROCKVILLE, Md., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host invest...
Posted: Feb 25, 2016
1
...
NextLast
= add release to Briefcase